Journal
EUROINTERVENTION
Volume 6, Issue 7, Pages 866-874Publisher
EUROPA EDITION
DOI: 10.4244/EIJV6I7A148
Keywords
Radiation physics; diagnostic cardiac catheterisation percutaneous coronary intervention
Categories
Funding
- Medtronic
- Merck and Co. Inc.
- Pfizer Inc.
- Portola Pharmaceuticals
- Eli Lilly and Company
- Servier
- Abbott
- Accumetrics
- Bracco
- Abiomed
- AlphaMedica
- Astra Zeneca
- Bristol-Myers Squibb
- Cariva
- Daiichi Sankyo
- Datascope
- Gilead
- Gerbet
- Regado
- St. Jude
- Therox
- Abbott Vascular
Ask authors/readers for more resources
Concerns regarding radiation exposure and its effects during pregnancy are often quoted as an important barrier preventing many women from pursuing a career in Interventional Cardiology. Finding the true risk of radiation exposure from performing cardiac catheterisation procedures can be challenging and guidelines for pregnancy exposure have been inadequate. The Women in Innovations group of Cardiologists with endorsement of the Society for Cardiovascular Angiography and Interventions aim to provide guidance in this publication by describing the risk of radiation exposure to pregnant physicians and cardiac catheterisation personnel, to educate on appropriate radiation monitoring and to encourage mechanisms to reduce radiation exposure. Current data do not suggest a significant increased risk to the fetus of pregnant women in the cardiac catheterisation laboratory and thus do not justify precluding pregnant physicians from performing procedures in the cardiac catheterisation laboratory. However, radiation exposure among pregnant physicians should be properly monitored and adequate radiation safety measures are still warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available